-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$42.8359.99% Upside
Immunovant, Inc. Frequently Asked Questions
-
What analysts cover Immunovant, Inc.?
Immunovant, Inc. has been rated by research analysts at H.C. Wainwright, Oppenheimer, Guggenheim, Piper Sandler, Goldman Sachs, UBS in the past 90 days.